{
    "nctId": "NCT02165605",
    "briefTitle": "HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer",
    "officialTitle": "Randomized, Double-Blind, Vehicle-Controlled Pilot Study of the Efficacy and Safety of HylaCareTM in the Treatment of Acute Skin Changes in Patients Undergoing External Beam Radiotherapy for Tumors of the Breast.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "Acute Skin Toxicity Per NCI-CTC v4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, age 18 or older\n* Diagnosis of breast cancer\n* Intact breast (not surgically absent)\n* Planned fractionated external beam radiotherapy to be delivered by opposing, tangential beams to 50.4 Gy in 28 fractions with a planned photon or electron boost of 10Gy in 5 fractions (for a total of 33 fractions)\n* Ability to understand and comply with the requirements of this study\n* Ability to give Informed Consent\n* For sexually active females, patient agrees to use acceptable method of birth control\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating\n* Use of concomitant skin care preparations at any of the treated or control portal areas to be observed\n* Any infection or unhealed wound of the radiotherapy portal areas, or generalized dermatitis\n* Severe renal failure creatinine \\> 3.0 within 6 months of study registration\n* Allergic history, including anaphylaxis or severe allergies to products in study serum or placebo\n* Planned relocation which would make follow-up visits impossible during the course of the study\n* Collagen vascular disease such as Lupus, or scleroderma",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}